Skip to main content
. 2021 May 26;125(4):510–519. doi: 10.1038/s41416-021-01405-x

Fig. 1. Study design (Part A reported here).

Fig. 1

ATM ataxia–telangiectasia-mutated kinase, DLX dose level X, NSCLC non-small-cell lung cancer, Q3W every 3 weeks, RECIST response evaluation criteria in solid tumours, SCLC small-cell lung cancer, TNBC triple-negative breast cancer, WT wild type.